Cargando…
Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy
Objective: Data on cellular and humoral immunogenicity after the third dose of anti-SARS-CoV-2 vaccines in patients with immune-mediated rheumatic diseases (IMRDs) are scarce. Herein, we evaluated the adaptive immune response in IMRD patients treated with different immunosuppressive therapies (conve...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525269/ https://www.ncbi.nlm.nih.gov/pubmed/37760858 http://dx.doi.org/10.3390/biomedicines11092418 |
_version_ | 1785110743505436672 |
---|---|
author | Mohamed Mohamed, Kauzar Álvarez-Hernández, María Paula Jiménez García, Carlos Guevara-Hoyer, Kissy Freites, Dalifer Martínez Prada, Cristina Pérez-Sancristóbal, Inés Fernández Gutiérrez, Benjamín Mato Chaín, Gloria Rodero, Maria Rodríguez de la Peña, Antonia Mulero, Teresa Bravo, Cecilia Toledano, Esther Culebras López, Esther Mediero Valeros, Beatriz Pérez Segura, Pedro Sánchez-Ramón, Silvia Candelas Rodríguez, Gloria |
author_facet | Mohamed Mohamed, Kauzar Álvarez-Hernández, María Paula Jiménez García, Carlos Guevara-Hoyer, Kissy Freites, Dalifer Martínez Prada, Cristina Pérez-Sancristóbal, Inés Fernández Gutiérrez, Benjamín Mato Chaín, Gloria Rodero, Maria Rodríguez de la Peña, Antonia Mulero, Teresa Bravo, Cecilia Toledano, Esther Culebras López, Esther Mediero Valeros, Beatriz Pérez Segura, Pedro Sánchez-Ramón, Silvia Candelas Rodríguez, Gloria |
author_sort | Mohamed Mohamed, Kauzar |
collection | PubMed |
description | Objective: Data on cellular and humoral immunogenicity after the third dose of anti-SARS-CoV-2 vaccines in patients with immune-mediated rheumatic diseases (IMRDs) are scarce. Herein, we evaluated the adaptive immune response in IMRD patients treated with different immunosuppressive therapies (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs], biological disease-modifying antirheumatic drugs [bDMARDs], and targeted synthetic disease-modifying antirheumatic drugs [tsDMARDs]) after the booster of the anti-SARS-CoV-2 vaccine to determine whether any drug reduced the vaccine’s response. Methods: A single-center prospective study was conducted, including patients presenting with IMRD and healthy controls (HC). Specific anti-SARS-CoV-2 interferon-gamma (IFN-γ) production was evaluated between 8–12 weeks after the third dose of the SARS-CoV-2 vaccine. In addition, anti-Spike IgG antibody titers were also measured. Results: Samples were obtained from 79 IMRD patients (51 women, 28 men; mean age 57 ± 11.3 years old): 43 rheumatoid arthritis, 10 psoriatic arthritis, 14 ankylosing spondylitis, 10 undifferentiated spondyloarthritis, and 2 inflammatory bowel disease-associated spondyloarthritis (IBD-SpA). In total, 31 HC (mean age 50.9 ± 13.1 years old, 67.7% women) were included in the study. Post-vaccine results displayed positive T-cell immune responses in 68 out of 79 (86.1%) IMRD patients (82.3% of those without prior COVID-19). All HC and IMRDs patients had an antibody response against the SARS-CoV-2 receptor-binding domain; however, the HC response was significantly higher (median of 18,048 AU/mL) than in IMRDs patients (median of 6590.3 AU/mL, p < 0.001). MTX and leflunomide were associated with lower titers of IgG and IFN-γ responses. Among bDMARDs, adalimumab, etanercept, and guselkumab are associated with reduced cellular responses. Conclusion: Our preliminary data show that the majority of our IMRD patients develop cellular and humoral responses after the SARS-CoV-2 booster vaccination, emphasizing the relevance of vaccination in this group. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. Specific vaccination protocols and personalized decisions about boosters are essential for these patients. |
format | Online Article Text |
id | pubmed-10525269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105252692023-09-28 Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy Mohamed Mohamed, Kauzar Álvarez-Hernández, María Paula Jiménez García, Carlos Guevara-Hoyer, Kissy Freites, Dalifer Martínez Prada, Cristina Pérez-Sancristóbal, Inés Fernández Gutiérrez, Benjamín Mato Chaín, Gloria Rodero, Maria Rodríguez de la Peña, Antonia Mulero, Teresa Bravo, Cecilia Toledano, Esther Culebras López, Esther Mediero Valeros, Beatriz Pérez Segura, Pedro Sánchez-Ramón, Silvia Candelas Rodríguez, Gloria Biomedicines Article Objective: Data on cellular and humoral immunogenicity after the third dose of anti-SARS-CoV-2 vaccines in patients with immune-mediated rheumatic diseases (IMRDs) are scarce. Herein, we evaluated the adaptive immune response in IMRD patients treated with different immunosuppressive therapies (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs], biological disease-modifying antirheumatic drugs [bDMARDs], and targeted synthetic disease-modifying antirheumatic drugs [tsDMARDs]) after the booster of the anti-SARS-CoV-2 vaccine to determine whether any drug reduced the vaccine’s response. Methods: A single-center prospective study was conducted, including patients presenting with IMRD and healthy controls (HC). Specific anti-SARS-CoV-2 interferon-gamma (IFN-γ) production was evaluated between 8–12 weeks after the third dose of the SARS-CoV-2 vaccine. In addition, anti-Spike IgG antibody titers were also measured. Results: Samples were obtained from 79 IMRD patients (51 women, 28 men; mean age 57 ± 11.3 years old): 43 rheumatoid arthritis, 10 psoriatic arthritis, 14 ankylosing spondylitis, 10 undifferentiated spondyloarthritis, and 2 inflammatory bowel disease-associated spondyloarthritis (IBD-SpA). In total, 31 HC (mean age 50.9 ± 13.1 years old, 67.7% women) were included in the study. Post-vaccine results displayed positive T-cell immune responses in 68 out of 79 (86.1%) IMRD patients (82.3% of those without prior COVID-19). All HC and IMRDs patients had an antibody response against the SARS-CoV-2 receptor-binding domain; however, the HC response was significantly higher (median of 18,048 AU/mL) than in IMRDs patients (median of 6590.3 AU/mL, p < 0.001). MTX and leflunomide were associated with lower titers of IgG and IFN-γ responses. Among bDMARDs, adalimumab, etanercept, and guselkumab are associated with reduced cellular responses. Conclusion: Our preliminary data show that the majority of our IMRD patients develop cellular and humoral responses after the SARS-CoV-2 booster vaccination, emphasizing the relevance of vaccination in this group. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. Specific vaccination protocols and personalized decisions about boosters are essential for these patients. MDPI 2023-08-29 /pmc/articles/PMC10525269/ /pubmed/37760858 http://dx.doi.org/10.3390/biomedicines11092418 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mohamed Mohamed, Kauzar Álvarez-Hernández, María Paula Jiménez García, Carlos Guevara-Hoyer, Kissy Freites, Dalifer Martínez Prada, Cristina Pérez-Sancristóbal, Inés Fernández Gutiérrez, Benjamín Mato Chaín, Gloria Rodero, Maria Rodríguez de la Peña, Antonia Mulero, Teresa Bravo, Cecilia Toledano, Esther Culebras López, Esther Mediero Valeros, Beatriz Pérez Segura, Pedro Sánchez-Ramón, Silvia Candelas Rodríguez, Gloria Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy |
title | Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy |
title_full | Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy |
title_fullStr | Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy |
title_full_unstemmed | Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy |
title_short | Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy |
title_sort | specific cellular and humoral response after the third dose of anti-sars-cov-2 rna vaccine in patients with immune-mediated rheumatic diseases on immunosuppressive therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525269/ https://www.ncbi.nlm.nih.gov/pubmed/37760858 http://dx.doi.org/10.3390/biomedicines11092418 |
work_keys_str_mv | AT mohamedmohamedkauzar specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT alvarezhernandezmariapaula specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT jimenezgarciacarlos specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT guevarahoyerkissy specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT freitesdalifer specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT martinezpradacristina specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT perezsancristobalines specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT fernandezgutierrezbenjamin specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT matochaingloria specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT roderomaria specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT rodriguezdelapenaantonia specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT muleroteresa specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT bravocecilia specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT toledanoesther specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT culebraslopezesther specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT medierovalerosbeatriz specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT perezsegurapedro specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT sanchezramonsilvia specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy AT candelasrodriguezgloria specificcellularandhumoralresponseafterthethirddoseofantisarscov2rnavaccineinpatientswithimmunemediatedrheumaticdiseasesonimmunosuppressivetherapy |